4D Molecular Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)

5 analysts have shared their evaluations of 4D Molecular Therapeutics FDMT during the recent three months, expressing a mix of bullish and bearish perspectives.

The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $49.4, a high estimate of $81.00, and a low estimate of $25.00. Observing a 31.73% increase, the current average has risen from the previous average price target of $37.50.

Interpreting Analyst Ratings: A Closer Look

In examining recent analyst actions, we gain insights into how financial experts perceive 4D Molecular Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to 4D Molecular Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.
• Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of 4D Molecular Therapeutics compared to the broader market.
• Price Targets: Analysts predict movements in price targets, offering estimates for 4D Molecular Therapeutics's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.

Capture valuable insights into 4D Molecular Therapeutics's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.

Stay up to date on 4D Molecular Therapeutics analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Get to Know 4D Molecular Therapeutics Better

4D Molecular Therapeutics Inc a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built portfolio of gene therapy product candidates focused in three therapeutic areas: ophthalmology (intravitreal vector), cardiology (intravenous vector) and pulmonology (aerosol vector). It has three product candidates in clinical trials: 4D-125 for the treatment of X-linked retinitis pigmentosa in a Phase 1/2 clinical trial, 4D-110 for the treatment of choroideremia in a Phase 1 clinical trial, and 4D-310 for the treatment of Fabry disease in a Phase 1/2 clinical trial. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration, and 4D-710 for the treatment of cystic fibrosis lung disease.

4D Molecular Therapeutics: Financial Performance Dissected

Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.

Revenue Growth: 4D Molecular Therapeutics displayed positive results in 3 months. As of 30 September, 2023, the company achieved a solid revenue growth rate of approximately 3940.8%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.

Net Margin: 4D Molecular Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -50.76% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): 4D Molecular Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -3.13% ROE, the company effectively utilizes shareholder equity capital.

Return on Assets (ROA): 4D Molecular Therapeutics's ROA stands out, surpassing industry averages. With an impressive ROA of -2.87%, the company demonstrates effective utilization of assets and strong financial performance.

Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.05.

The Significance of Analyst Ratings Explained

Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.

Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.

This article was generated by Benzinga's automated content engine and reviewed by an editor.